1
|
Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naito K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S. Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy. Anticancer Res 2020; 40:4763-4771. [PMID: 32727803 DOI: 10.21873/anticanres.14478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 06/21/2020] [Accepted: 06/22/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated. RESULTS The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapy-associated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group. CONCLUSION First-line chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.
Collapse
Affiliation(s)
- Teppei Yamada
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan .,Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshiki Maeda
- Department of Preventive Medicine and Public Health, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Gumpei Yoshimatsu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.,Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Kanefumi Yamashita
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Akira Komono
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Ryuji Kajitani
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yoshiko Matsumoto
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Hideki Nagano
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | | | | | - Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Fumihiro Yoshimura
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoaki Sakata
- Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Shohta Kodama
- Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| |
Collapse
|
2
|
Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S. Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study. Anticancer Res 2019; 39:4525-4532. [PMID: 31366555 DOI: 10.21873/anticanres.13629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 06/18/2019] [Accepted: 06/19/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cells vaccination (DCs), in combination with 1st-line chemotherapies in terms of the survival of patients with advanced colorectal cancer (CRC). PATIENTS AND METHODS A total of 198 patients who were diagnosed with advanced CRC and administered 1st-line chemotherapies were enrolled in this study. The correlation between overall survival (OS) and various clinical factors was examined by univariate and multivariate analyses. RESULTS Univariate analyses revealed that the prognosis was improved in CRC patients who received immune-cell therapy with PS 0, bevacizumab (BV), and capecitabine-including regimens (Cap). Finally, multivariate analysis demonstrated that PS=0, and the combination of immune-cell therapy and Cap provided a survival benefit in patients with advanced CRC. CONCLUSION The survival benefit could be potentially obtained with better PS by the combination of immune-cell therapy and Cap as a 1st-line setting in patients with CRC.
Collapse
Affiliation(s)
- Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan .,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | | | | | | | | | | | | | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|
3
|
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S. Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. Anticancer Res 2018; 38:4353-4360. [PMID: 29970573 DOI: 10.21873/anticanres.12736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 06/07/2018] [Accepted: 06/18/2018] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. MATERIALS AND METHODS The correlation between overall survival (OS) and various factors including sex, age, performance status (PS), distant metastasis, chemotherapy, radiotherapy, and type of immune-cell therapy were evaluated by univariate and multivariate analyses. RESULTS The median OS of advanced or recurrent pancreatic cancer was 5.8 months, and the prognosis was improved in pancreatic cancer patients who received immune-cell therapy with PS scores of 0-1 [hazard risk (HR)=0.56; 95% confidence interval (CI)=0.46-0.68; p<0.0001], chemotherapy (HR=0.68; 95%CI=0.54-0.87; p=0.002), or radiotherapy (HR=0.76; 95%CI=0.63-0.93; p=0.006). Multivariate analysis demonstrated that distant metastasis indicated a poor prognosis for pancreatic cancer patients that were administered immune-cell therapy (HR=1.62; 95%CI=1.37-1.93; p<0.0001). Additionally, the combined immune-cell therapy with αβ T cell and dendritic cell (DC) vaccine provided a survival benefit in advanced or recurrent pancreatic cancer patients (HR=0.69; 95%CI=0.57-0.83; p<0.0001). CONCLUSION A survival benefit could be potentially obtained with better PS by the combination of αβ T cell therapy, DC vaccine therapy, and chemotherapy at an early stage in pancreatic cancer.
Collapse
Affiliation(s)
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan
- Department of Next Generation Cell and Immune therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | | | | | | | | | | | - Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan
- Department of Next Generation Cell and Immune therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan
- Department of Next Generation Cell and Immune therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|